AFFINITY ENERGY AND HEALTH Forum: Community User: Green

Corporate Overview Board Rationalisation During the quarter under review the Company has undertaken further Board and management rationalisation with the resignation of Mr. Sonu Cheema and the appointment of Mr Qing Xu as Non- Executive Director. Subsequent to the quarter the Company announced the appointment of Mr Terry Gardiner to the Board as Non-Executive Director and the resignation of Mr Josh Puckridge. Mr Gardiner has more than 20 years’ experience in the capital markets and provides corporate advisory services to listed companies in Australia and oversesas. Mr Gardiner is an Executive Director of Barclay Wells Limited, a boutique stockbrocking firm with offices in Perth and Melbourne. Mr Gardiner is Non-Executive Director of Roto-Gro International Limited and was an integral contributor to Roto-Gro’s successful IPO and continues to be a valuable adviser on Roto-Gro’s strategies. AEB welcomes Mr Gardiner’s relevant industry experience to the board of the Company. Mr Gardiner is also Non-Executive Director of ASX listed Australian mineral resource explorers Galan Lithium Limited and Cazaly Resources Limited. Financing To facilitate the ongoing commercialisation of the Company’s proprietary algae technology and medicinal cannabis operations in Malta and Australia, the Company is presently finalising discussions with regards how to best facilitate a significant capital injection to the Company that will ideally take the form of a small portion of convertible equity and a significant amount of direct normal equity. The Company’s preference is to puruse a mechanism that supports current shareholders to participate. -ENDS

September Quarter Operational Summary: Algae Division Overview Production The Company has now developed the proprietary algae technology for nutraceuticals to the point where negotiations are being undertaken to issue a sub-licence in North America. Discussions continue in this regard however the Company is targeting a cash payment and ongoing royalties for and from the sub-licence. These discussions include the possible sale of the Atlanta based product development plant. As a result of ceasing production in the short term the ongoing costs at the Atlanta facility have been significantly reduced. The Company will update the market accordingly should any of these possibilities materially progress to the point where they become an announceable event. Medicinal Cannabis Division Overview Australian Medicinal Cannabis License At the end of the Quarter under review the Company is still underway with the Office of Drug Control (“ODC”). The Company will update accordingly. European Medicinal Cannabis License In accordance with the Letter of Intent issued by Malta Enterprise (Maltese Government authority) the Company has been allocated a 2,200m2 parcel of land on which to establish the medicinal cannabis facilities in Malta. AEB has been allocated factory space of 580sqm to start operations until such time the 2,200m2 parcel of land allocated is developed. The Company is progressing with formal documents and initial fit out plans. Other Opportunities The Company is in various discussions with potential strategic partners regarding the development of an algae/cannabis neutraceutical product as well as cannabis strain genetics to coincide with the development of the Australian (if and when issued) and Maltese licence.

Plant-based health and well-being company Affinity Energy & Health Limited (“Affinity” or the “Company”) (ASX:AEB) is pleased to provide shareholders with its Quarterly Activities Report for the three months ended 30 September 2019 (Period). Key Points: Algae Operations • Staffing reduced significantly • Cost rationalisation reduces overheads Medicinal Cannabis • Australian Update o Cultivation and Manufacturing License applications are both in the Evaluation phase of the Office of Drug Control (“ODC”) process. • Malta Application o Malta Industrial Parks (Maltese Government authority) has identified land and an existing building for the Company to establish medicinal cannabis facilities and the Company is progressing with formal documents and initial fit out plans. • Corporate o Board and management rationalisation continued o Financing and relisting process underway and will be announced within the current Period

https://***.com.au/threads/ann-quarterly-activities-report-and-appendix-4c.5050003/

Aktivitätsbericht ist raus und klingt soooo schlecht nicht

Danke heavy

Wahnsinn, hier kann man nicht mal l äch er lich schreiben

***

Verlängerung bis 12.11.

Gibt aber noch keine Meldung

Also in aus war bisher kein Handel und die sind ja ein paar Stunden voraus. Wird somit nix.. Frage mich aber auch, was soll passieren, das kerngeschäft geben Sie ab, für Cannabis sind sie 3 Jahre zu spät. Die Geschäftsführer und Direktoren wechseln fleißig durch und Geld ist auch nicht mehr da. Sorry, dass ich etwas schwarzmale, aber Peter hatfull hat mir 2015 ganz andere Dinge geschrieben und den Fortschritt versprochen, eingehalten wurde nichts.

Ein Traum ist doch legitim. Schauen wir mal

Er träumt auch..... von sitv.......😂😂😂😂😂

Bisher nix gelesen

@Saravol - träumen darf man ja ;)

Hm, ich hab da so einen Verdacht 😉